Ike Greenstein 11/4/24 Ike Greenstein 11/4/24 Oak Hill Bio and Chiesi Group Announce First European Patient Enrolled in the Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia in Premature Infants Read More Ike Greenstein 10/7/24 Ike Greenstein 10/7/24 Oak Hill Bio Announces Promotion of Josh Distler to Chief Executive Officer and Additional Updates to Executive Team and Board Read More Rachel Swansburg 5/17/24 Rachel Swansburg 5/17/24 Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia in Premature Infants Read More Rachel Swansburg 1/9/24 Rachel Swansburg 1/9/24 Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy Read More Jamison Wright 9/2/22 Jamison Wright 9/2/22 Oak Hill Bio to Participate in Citi 17th Annual BioPharma Conference Read More Jamison Wright 8/25/22 Jamison Wright 8/25/22 Oak Hill Bio Joins C-Path’s International Neonatal Consortium Read More Jamison Wright 5/27/22 Jamison Wright 5/27/22 Oak Hill Bio to Participate in 2022 Wells Fargo Private Biotech Symposium Read More Jamison Wright 5/25/22 Jamison Wright 5/25/22 Oak Hill Bio Sponsors Industry Symposium at International Conference on Clinical Neonatology Read More Jamison Wright 5/17/22 Jamison Wright 5/17/22 2022 RBC Capital Markets Global Healthcare Conference Read More Jamison Wright 5/12/22 Jamison Wright 5/12/22 Oak Hill Bio to Present at 2022 RBC Capital Markets Global Healthcare Conference Read More 2/1/22 2/1/22 Oak Hill Bio Launches with Pipeline and Senior Leadership from Takeda Read More
Ike Greenstein 11/4/24 Ike Greenstein 11/4/24 Oak Hill Bio and Chiesi Group Announce First European Patient Enrolled in the Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia in Premature Infants Read More
Ike Greenstein 10/7/24 Ike Greenstein 10/7/24 Oak Hill Bio Announces Promotion of Josh Distler to Chief Executive Officer and Additional Updates to Executive Team and Board Read More
Rachel Swansburg 5/17/24 Rachel Swansburg 5/17/24 Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia in Premature Infants Read More
Rachel Swansburg 1/9/24 Rachel Swansburg 1/9/24 Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy Read More
Jamison Wright 9/2/22 Jamison Wright 9/2/22 Oak Hill Bio to Participate in Citi 17th Annual BioPharma Conference Read More
Jamison Wright 8/25/22 Jamison Wright 8/25/22 Oak Hill Bio Joins C-Path’s International Neonatal Consortium Read More
Jamison Wright 5/27/22 Jamison Wright 5/27/22 Oak Hill Bio to Participate in 2022 Wells Fargo Private Biotech Symposium Read More
Jamison Wright 5/25/22 Jamison Wright 5/25/22 Oak Hill Bio Sponsors Industry Symposium at International Conference on Clinical Neonatology Read More
Jamison Wright 5/17/22 Jamison Wright 5/17/22 2022 RBC Capital Markets Global Healthcare Conference Read More
Jamison Wright 5/12/22 Jamison Wright 5/12/22 Oak Hill Bio to Present at 2022 RBC Capital Markets Global Healthcare Conference Read More
